Anebulo Pharmaceuticals, Inc. (ANEB) shareholders
ANEBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.00+0.00 (+75.00%)
Close on Oct 19, 2026Market cap $28.76KP/E –Yield –
Ownership
Institutional holdings as of Mar 31, 2026, from 13F filings
Held by institutions
0.0%
0M of 41M shares
Institutional holders
0
0 new, 18 sold out
Net institutional buying
-22M
In Q1 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Aron R. English Joint filing with 22 Nw Fund, LP (40.10%), Pharma Investors, LLC (11.30%) | 21,929,880 | 51.10% | 13D (active) amendment | Feb 24, 2025 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (8.53%), Daniel Mack (8.53%) | 3,547,398 | 8.53% | 13G (passive) amendment | Dec 31, 2025 |
| Nathaniel August Joint filing with Mangrove Partners IM, LLC (6.15%) | 2,525,252 | 6.15% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Dec 31, 2025
| Holder | Shares | % of ANEB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| 22NW, LP | 15,467,300 | 37.92% | $84.76M | – | 35.68% |
| Nantahala Capital Management, LLC | 3,036,325 | 7.44% | $3.07M | – | 0.10% |
| Mangrove Partners | 2,525,252 | 6.19% | $2.55M | – | 0.21% |
| Vanguard Group Inc | 435,821 | 1.07% | $440.18K | +129,281 | 0.00% |
| Morgan Stanley | 399,404 | 0.98% | $403.40K | – | 0.00% |
| Geode Capital Management, LLC | 160,760 | 0.39% | $162.48K | −13,348 | 0.00% |
| Rangeley Capital, LLC | 50,000 | 0.12% | $50.50K | +30,000 | 0.04% |
| Renaissance Technologies LLC | 25,098 | 0.06% | $25.35K | −3,402 | 0.00% |
| Citadel Advisors LLC | 24,239 | 0.06% | $24.48K | New | 0.00% |
| BlackRock, Inc. | 23,790 | 0.06% | $24.03K | −270 | 0.00% |
| Northern Trust Corp | 21,994 | 0.05% | $22.21K | −2,399 | 0.00% |
| Ikarian Capital, LLC | 17,736 | 0.04% | $17.91K | −139,984 | 0.00% |
| State Street Corp | 12,768 | 0.03% | $12.90K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,230 | 0.01% | $3.26K | +1,480 | 0.00% |
| UBS Group AG | 2,334 | 0.01% | $2.36K | +2,114 | 0.00% |
| JPMorgan Chase & Co | 2,253 | 0.01% | $2.28K | −2,023 | 0.00% |
| Bank Of America Corp /De/ | 382 | 0.00% | $386 | −509 | 0.00% |
| FNY Investment Advisers, LLC | 100 | 0.00% | $0 | +5 | 0.00% |
| Royal Bank of Canada | 30 | 0.00% | $0 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 0 | 0M | 0.0% | 0 / 0 | 0 / 18 | 0M | 22M |
| Q4 2025 | 19 | 22M | 54.5% | 2 / 5 | 7 / 4 | 0M | 0M |
| Q3 2025 | 21 | 22M | 54.5% | 9 / 4 | 3 / 6 | 0M | 1M |
| Q2 2025 | 18 | 23M | 55.4% | 2 / 6 | 3 / 2 | 0M | 0M |
| Q1 2025 | 18 | 23M | 55.5% | 4 / 5 | 4 / 1 | 0M | 0M |
| Q4 2024 | 15 | 23M | 55.3% | 2 / 6 | 5 / 0 | 15M | 0M |
| Q3 2024 | 13 | 7M | 18.0% | 2 / 3 | 4 / 1 | 0M | 1M |
| Q2 2024 | 13 | 8M | 19.2% | 1 / 5 | 3 / 3 | 1M | 1M |
| Q1 2024 | 15 | 8M | 19.9% | 4 / 3 | 5 / 3 | 0M | 1M |
| Q4 2023 | 14 | 8M | 20.1% | 4 / 5 | 3 / 2 | 2M | 1M |
| Q3 2023 | 12 | 7M | 17.3% | 0 / 5 | 2 / 0 | 0M | 0M |
| Q2 2023 | 12 | 7M | 17.2% | 3 / 2 | 2 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Cunningham, Richard Anthony | Chief Executive Officer, Director | – | – | Apr 7, 2025 |
| Kenneth C. Cundy | Chief Scientific Officer | – | – | Apr 7, 2025 |
| Areta Kupchyk | Director | – | – | Apr 7, 2025 |
| Joseph F. Lawler | Director, 10% owner | 12,000,000 | 29.42% | Apr 7, 2025 |
| Kenneth Lin | Director | – | – | Apr 7, 2025 |
| Nathaniel Calloway | Director | – | – | Apr 7, 2025 |
| Bimal R. Shah | Director | – | – | Apr 7, 2025 |
| Aron R. English | Director, 10% owner | 20,121,828 | 49.34% | Apr 7, 2025 |
| Jason Aryeh | Director | – | – | Apr 7, 2025 |
| 22NW Fund, LP | 10% owner | 8,017,241 | 19.66% | Dec 26, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Aron R. English Director, 10% owner | Dec 23, 2024 | Buy | +10,101,010 | $0.99 | $10.00M | 15,467,300 |
| 22nw, Lp 10% owner | Dec 18, 2023 | Gift | +300,000 | – | – | 5,366,290 |
| 22nw, Lp 10% owner | Dec 18, 2023 | Gift | −300,000 | – | – | 0 |
| 22nw, Lp 10% owner | Nov 13, 2023 | Award | +300,000 | – | – | 300,000 |
| Aron R. English Director, 10% owner | Sep 28, 2022 | Award | +1,703,577 | $2.81 | $4.79M | 5,066,290 |
| 22NW Fund, LP – | Dec 17, 2021 | Buy | +400 | $6.59 | $2.64K | 3,362,713 |
| 22NW Fund, LP – | Dec 14, 2021 | Buy | +412 | $5.90 | $2.43K | 3,362,313 |
| 22NW Fund, LP – | Dec 3, 2021 | Buy | +4,500 | $5.93 | $26.69K | 3,361,901 |
| 22NW Fund, LP – | Dec 2, 2021 | Buy | +13,836 | $5.30 | $73.33K | 3,357,401 |
| 22NW Fund, LP 10% owner | May 6, 2021 | Award | +714,250 | $7.00 | $5.00M | 3,343,565 |
| 22nw, Lp 10% owner | May 6, 2021 | Award | +714,286 | $7.00 | $5.00M | 3,343,601 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1000.0
At 0M shares a day
Change since last report
0.0%
From 0M shares
Short volume, 20 days
47.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Anebulo Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?